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Cylindromatosis Tumor Suppressor Protein
(CYLD) Deubiquitinase is Necessary for Proper
Ubiquitination and Degradation of the
Epidermal Growth Factor Receptor*□S
Virginia Sanchez-Quiles‡¶, Vyacheslav Akimov‡, Nerea Osinalde‡**,
Chiara Francavilla§, Michele Puglia‡, Inigo Barrio-Hernandez‡, Irina Kratchmarova‡,
Jesper V. Olsen§, and Blagoy Blagoev‡ ‡‡
Cylindromatosis tumor suppressor protein (CYLD) is a
deubiquitinase, best known as an essential negative reg-
ulator of the NFkB pathway. Previous studies have sug-
gested an involvement of CYLD in epidermal growth fac-
tor (EGF)-dependent signal transduction as well, as it
was found enriched within the tyrosine-phosphorylated
complexes in cells stimulated with the growth factor. EGF
receptor (EGFR) signaling participates in central cellular
processes and its tight regulation, partly through ubiquiti-
nation cascades, is decisive for a balanced cellular
homeostasis. Here, using a combination of mass spec-
trometry-based quantitative proteomic approaches with
biochemical and immunofluorescence strategies, we
demonstrate the involvement of CYLD in the regulation
of the ubiquitination events triggered by EGF. Our data
show that CYLD regulates the magnitude of ubiquitina-
tion of several major effectors of the EGFR pathway by
assisting the recruitment of the ubiquitin ligase Cbl-b to
the activated EGFR complex. Notably, CYLD facilitates
the interaction of EGFR with Cbl-b through its Tyr15
phosphorylation in response to EGF, which leads to
fine-tuning of the receptor’s ubiquitination and subsequent
degradation. This represents a previously uncharacterized
strategy exerted by this deubiquitinase and tumors sup-
pressor for the negative regulation of a tumorigenic signal-
ing pathway. Molecular & Cellular Proteomics 16:
10.1074/mcp.M116.066423, 1433–1446, 2017.
Epidermal Growth Factor Receptor (EGFR)1 belongs to the
family of receptor tyrosine kinases (RTKs) and plays a crucial
role in the maintenance of a correct cellular homeostasis,
controlling central processes such as cell proliferation, migra-
tion, differentiation or survival (reviewed in (1)). EGFR consists
of an extracellular domain for the recognition of the ligands, a
single pass transmembrane region and an intracellular tyro-
sine kinase- containing domain. The binding of a ligand, such
as Epidermal Growth Factor (EGF), promotes the dimerization
of the receptor and the subsequent activation of its kinase
activity, which further leads to the autophosphorylation of
tyrosine residues on the intracellular region of the EGFR (1, 2).
These modified residues act as docking sites for recruiting
SH2 or PTB domain- containing signaling proteins (3, 4),
hence the stimulation triggers the association of large intra-
cellular complexes that support rapid spread and amplifica-
tion of the signal, eventually resulting in a specific cellular
output (5).
To facilitate an adequate response in intensity and duration,
the downstream events following the activation of the recep-
tor necessitate tight negative regulation that counteracts the
positive signals. In this regard, the attachment of ubiquitin
moieties to the EGFR plays a key role in directing its internal-
ization and further endocytic trafficking that eventually leads
to its lysosomal degradation or recycling (6, 7). Hence, the
regulated turnover of EGFR is pivotal for a correct cellular
output. E3 ubiquitin ligases of the casitas B-lineage lym-
phoma (Cbl) family play a crucial part in this chain of events.
Cbl proteins are recruited to activated receptors, either bind-
ing directly to their phosphorylated tyrosine residues or
through the assistance of other adaptor proteins (8), thereby
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ubiquitinating the EGFR, which can in turn be recognized and
sorted by the endocytic machinery (9, 10). In this context,
further level of signaling modulation can be reached by ubiq-
uitin hydrolases (deubiquitinases, DUBs), which may oppose
the activity of Cbl ligases by removing ubiquitin moieties from
the receptor (11, 12). These latter enzymes can thereby have
a decisive role for the final cellular response.
Cylindromatosis protein (CYLD) is a tumor suppressor that
displays a specific ubiquitin hydrolase activity for K63-linked
polyubiquitin chains (13). Negative regulatory actions of CYLD
have been reported for several signaling paradigms, the most
explored to date being its role in the NF-kB pathway (14–16).
It has also been shown an involvement of CYLD in the control
of essential cellular processes as apoptosis (14–16), inflam-
mation (17), proliferation (18) and tumorigenesis (19). The
downregulation of this DUB has been linked with oncogenesis
in different cellular contexts including melanoma (20), my-
eloma (21), uterine cervix carcinoma (22), hepatocellular and
colon carcinoma (23).
To our knowledge, the investigation of CYLD and its spec-
trum of actions have mostly been carried out through targeted
approaches that explored, one at a time, the different regula-
tory strategies of this DUB on specific, discrete targets. How-
ever, advances in quantitative mass spectrometry (MS)-based
proteomics allow studies of signaling cascades in a system-
wide, unbiased manner for uncovering novel molecular char-
acters with a key part in the transduction mechanisms. Cur-
rently, MS-based quantitative proteomics represents a powerful
tool for the comprehensive characterization of signaling net-
works (24, 25), including their dynamics changes (26–28),
protein interactions (29, 30) and numerous post-translational
modifications (31). Indeed, the first evidences pointing to an
involvement of CYLD in the molecular events downstream
the EGFR were obtained by MS-based proteomics (32).
Following addition of EGF, the presence of CYLD among the
tyrosine-phosphorylated complexes showed a very rapid
and strong increase, which could indicate a role for this
deubiquitinase in the RTK signaling and make CYLD-related
ubiquitination events in EGFR pathway worth investigating.
Here, we conducted a global analysis of the cellular ubiq-
uitinome by employing a recently described approach termed
StUbEx (Stable Tagged Ubiquitin Exchange) followed by MS-
based quantitative proteomics (33). This, in combination with
protein and peptide pull-down assays, uncovered an unex-
pected role for CYLD as a key factor for proper ubiquitination
of the EGFR and downstream signaling components. Namely,
ubiquitination state of the activated receptor is compromised
in the absence of CYLD, which results in a decreased receptor
degradation. We demonstrate herein that CYLD interacts with
the ubiquitin ligase Cbl-b, contributing to the recruitment of
the later to the EGFR in response to EGF stimulation. Our
findings provide a yet uncharacterized and intriguing strategy
of CYLD for the negative modulation of signaling pathways,
hence reinforcing and expanding the mechanisms underlying
its role as a tumor suppressor.
EXPERIMENTAL PROCEDURES
Cell Culture—Human cervix epithelial adenocarcinoma HeLa cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM, Lonza,
Basel, Switzerland) supplemented with 10% Fetal Bovine Serum, 1%
Penicillin-Streptomycin, and 1% L-Glutamine. Ovarian and laryngeal
carcinoma cells (Skov3 and Hep2, respectively) were cultured using
the same medium. For labeling experiments, cells were grown in light,
medium or heavy DMEM media, containing either L-arginine (Arg0)
and L-lysine (Lys0), L-arginine-13C6
14N4 (Arg6) and L-lysine-
2H4 (Lys4)
or L-arginine-13C6
15N4 (Arg10) and L-lysine-
13C6
15N2 (Lys8), respec-
tively, as previously described (27). For EGF stimulation, cells were
grown to a confluency of 70%, starved without serum for 16 h and
stimulated with 150 ng/ml of EGF for the indicated times. When using
inhibitors, those were added to the starving media 30 min prior the
stimulation and present while treating with the growth factor. EGFR
inhibitors (Iressa and CI1033) and Akt inhibitor MK2206 were pur-
chased from Selleckchem (Houston, TX) whereas MEK inhibitor
U0126 was from Promega (Madison, WI). Where indicated, 10 g/ml
cycloheximide (Sigma-Aldrich, St. Louis, MO) was used to block the
de novo protein synthesis.
RNAi-based Silencing and Rescue Expression of Wild Type and
Y15F Mutant of CYLD—DNA constructs for RNAi silencing of CYLD
and generation of stable cell lines were performed using a lentiviral
system as described before (33). We used the following targeting
sequences for RNAi: 5-GCAATATGACGAGTTAGTA-3 for shControl
and 5-GGGTAGAACCTTTGCTAAA-3 for shCYLD. Depletion of
CYLD was confirmed by real-time PCR and immunoblotting (see
Supplemental Data for details). A sequence-verified cDNA clone of
CYLD was acquired from I.M.A.G.E. consortium (IRAUp969D0565D).
RNAi-resistant cDNA of CYLD was created by mutating 8 nucleotides
(indicated in capitals below) in the sequence targeted by the shRNA,
but maintaining the amino acid code. The following primer was used
for this purpose: 5-ttgaatattctgtttcatcatattttaagAgtTgaGccCCtCTtG-
aaaataagatcagcaggtcaaaagg-3. Using methods of conventional
cloning, the RNAi-resistant cDNA was then sub-cloned into the
shCYLD vector with the Flag-epitope sequence at the N terminus and
under control of EF1a promoter (construct named shCYLD-Flag-WT-
CYLD). A mutant expressing CYLD with tyrosine exchanged with
phenylalanine at position 15 was created by conventional methods of
site-directed DNA mutagenesis (construct named shCYLD-Flag-
Y15F-CYLD). HeLa cells with CYLD KD (shCYLD) were used to create
clones expressing shCYLD-Flag-WT-CYLD and shCYLD-Flag-Y15F-
CYLD constructs with the lentiviral delivery method as described
above.
Immunoblotting, Immunoprecipitation, and Immunofluorescence—
Antibodies used for immunoblotting were from Santa Cruz Biotech-
nology (Dallas, TX) (CYLD, Cbl-b), BD Transduction Laboratories (San
Jose, CA) (c-Cbl), Millipore (Billerica, MA) (EGFR), Enzo Life Sciences
(Farmingdale, NY) (Ubiquitin), Sigma (-Tubulin), or Cell Signaling
Technology (Danvers, MA) (phospho-Akt Ser473, Akt, phosphor-
Erk1/2 Thr202/Tyr204, Erk).
For immunoprecipitation experiments, proteins were extracted in
ice-cold modified RIPA buffer (50 mM Tris/HCl pH 8.0, 150 mM NaCl,
1% (v/v) Nonidet P-40, 0.25% Sodium Deoxycholate) supplemented
with proteases and phosphatases inhibitors (both from Roche). The
antibodies used for immunoprecipitation of phosphorylated-tyrosine
containing complexes were from Millipore (clone 4G10) and from Cell
Signaling Technology (P-Tyr-100). Antibodies sc-120 and 06-847,
from Santa Cruz Biotechnology and Millipore respectively, were used
for the immunoprecipitation of the EGFR. CYLD and Cbl-b proteins
were immunoprecipitated using the antibodies sc-137139, sc-1704
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and sc-8006, from Santa Cruz Biotechnology. For control immuno-
precipitations, an antibody against the GFP protein (sc-9996, Santa
Cruz Biotechnology) was used. For immunoprecipitation of the Flag-
tagged WT and Y15F CYLD, lysates were prepared in RIPA buffer,
further incubated for 30 min with 1% SDS to disrupt protein-protein
interactions and then diluted to 0.05% SDS with RIPA buffer to
perform the immunoprecipitation using Anti-Flag M2 Affinity Agarose
Gel (Sigma-Aldrich).
For immunofluorescence, HeLa cells were transfected with GFP-
Rab7 plasmid and lipofectamine as described previously (34). Anti-
body sc-120 from Santa Cruz was used for detection of EGFR (see
supplemental Data for details).
StUbEx and Peptide Pull-down Analyses—For the enrichment of
ubiquitinated proteins, shControl and shCYLD HeLa cells containing
the StUbEx construct (33) were grown in the presence of doxycycline
60 h prior the experiment. Cells were subjected to serum starvation
and stimulated with 150 ng/ml of EGF as indicated. To study the four
conditions of interest, two paralleled triple SILAC experiments were
performed per replica (we carried out two biological replicas, thus
corresponding to a total of four triple SILAC experiments; the exper-
imental design of one replica is exemplified in Fig. 2A). Cells were
lysed in a 50 mM phosphate buffer pH 8.0 containing 6 M Guanidine-
HCl and 500 mM NaCl. The subsequent enrichment of ubiquitinated
proteins was performed as described previously (33).
For immunoprecipitation and peptide pull-down of CYLD, cells
were lysed in ice-cold modified RIPA buffer (50 mM Tris/HCl pH 8.0,
150 mM NaCl, 1% (v/v) Nonidet P-40, 0.25% Sodium Deoxycholate)
containing proteases and phosphatases inhibitors (both from Roche).
Lysates were cleared and protein extracts from the differently labeled
conditions were quantified. CYLD antibody (Santa Cruz Biotechnol-
ogy) coupled to protein A Sepharose beads was used for the immu-
noprecipitation. The peptide pull-down experiments were performed
as described (35), using the following sequences: SGSQEKVTSP-pY-
WEERIF and the unmodified counterpart SGSQEKVTSPYWEERIF. An
empty-beads pull-down was carried out in the light condition to
discriminate unspecific background proteins (see supplemental Data
for details).
NanoLC Tandem Mass Spectrometry (LC-MS/MS) and Data Anal-
ysis—Peptides were separated by reversed-phase in an EASY-nLC
1000 (Thermo Scientific) coupled to a mass spectrometer equipped
with a nanoelectrospray ion source. The samples were analyzed in
either an LTQ Orbitrap Velos or a Q Exactive (Thermo Scientific). For
the chromatographic separation, solvent A was 0.5% acetic acid and
solvent B was 80% acetonitrile in 0.5% acetic acid. The peptides
were eluted from an analytical in-house packed column of ReproSil
Pur C18-AQ, 3 m resin (Dr Maisch GmbH), at a flow rate of 250
nL/min. The mass spectrometers were operated in positive ionization
mode, in a top 12 data-dependent manner, at a resolution of 70,000
(at m/z 400) and AGC target of 1e6 for the MS survey, scanning from
300 to 1750 m/z. For the MS/MS analysis, resolution was set to
35,000 (at m/z 400), AGC target to 1e5, minimum intensity to 4e4 and
isolation window to 2.0 m/z. To minimize the repeated fragmentation
of ions, an exclusion time of 45 s was programmed. The maximum
injection time values for survey and MS/MS scans were 120ms and
124ms, respectively.
Raw data files were analyzed with MaxQuant (36) version 1.3.0.5,
which includes the Andromeda search engine. Peak lists were
searched against human UniProt database version 2014.01 (88479
sequence entries). Three SILAC labeling channels were set, corre-
sponding to Lys0/Arg0, Lys4/Arg6 and Lys8/Arg10 for the light, me-
dium and heavy conditions, respectively. Variable modifications for
the searches included N-terminal protein acetylation, methionine ox-
idation, deamidation of asparagine and glutamine. In addition, phos-
phorylation on serine, threonine and tyrosine residues was included
as variable modification for the searches from the peptide-pull-downs
and CYLD-IP experiments, whereas di-glycyl variable modification on
lysine was set in the StUbEx searches to account for protein ubiq-
uitination. Carbamidomethylation of cysteine was set as fixed modi-
fication for all experiments. The maximum number of modifications
accepted per peptide was five and the minimum peptide length was
set to seven amino acids. Trypsin was used as protease with a
maximum of two missed cleavages. Peptides were identified with
mass tolerance of 7 ppm for precursors and 20 ppm for fragment
ions. Both peptide and protein maximum false discovery rates (FDR)
were set to 0.01 based on the target-decoy approach. Known com-
mon contaminants, as specified in MaxQuant, we excluded from the
identification.
Parallel Reaction Monitoring (PRM) Analysis—All PRM analyses
were performed on a Q Exactive HF (Thermo Scientific) using the
same LC-MS/MS system previously described with the following
method modifications. Precursor m/z of proteotypic target peptides
for EGFR, Cbl-b, CYLD, and FLNA (supplemental Table S8) have been
selected from previous top 12 data-dependent runs and added to the
instrument inclusion list. MS/MS spectra of target peptides were
acquired in unscheduled PRM mode using a resolution of 60,000 (at
m/z 200) and an AGC target of 5e5 with a maximum injection time of
150–200ms (37, 38). Fragmentation was performed in HCD mode
with normalized collision energy of 28. PRM data analysis was carried
out on Skyline™ 3.6.0 software (39). Spectral libraries were built using
MaxQuant ms/ms search files. Resolving power and mass analyzer
were set respectively to 60.000 and Orbitrap. Area under the curve
(AUC) values relative to the 4–6 most intense product ions for each
peptide were exported and plotted in a matrix which was used for
further statistical analysis (supplemental Table S8). Total MS2 frag-
ments AUC values for EGFR recycling (3 biological replicas) and
Cbl-b Co-IP (2 biological replicas) analysis were normalized using the
housekeeping protein Filamin-A or the Co-IP antigen Cbl-b, respec-
tively. All the Skyline data, MaxQuant searches, and .raw files have
been deposited to the ProteomeXchange Consortium via the PRIDE
partner repository.
Experimental Design and Statistical Rationale—Four triple SILAC
experiments corresponding to two full biological replicas were per-
formed for the described StUbEx experiments. Two biological repli-
cates were performed for peptide pull-down experiments per exper-
iment, swapping medium and heavy SILAC conditions to avoid any
technical bias. A control condition, in which the light SILAC protein
extract was incubated with empty beads, was included in both pull-
down experiments, helping to discriminate background and contam-
inant signals. In the case of CYLD immunoprecipitation, two biological
replicates we performed as well.
The visualization of overlapping protein identifications was per-
formed using the BioVenn web application (http://www.cmbi.ru.nl/
cdd/biovenn/), whereas the significance of the changes in SILAC
protein ratios were based on significance B calculations inbuilt in the
MaxQuant/Perseus software and visualized with GProX (40). The
analysis of functional groups and GO term categories were carried out
in MetaCore (Thomson Reuters), which relies on Fisher statistical test
with an FDR adjusted p values.
RESULTS
CYLD is Enriched in Early Tyr-phosphorylated Complexes
Upon EGF Stimulation—EGFR pathway drives central cellular
processes and, hence, its fine-tuned regulation is crucial for
the maintenance of a correct cellular homeostasis. Therefore,
the characterization of the molecular events downstream this
RTK constitutes a powerful strategy for understanding both
healthy and pathological mechanisms of the cell. In previous
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proteomics studies aiming at gaining insights into the molec-
ular players involved in the EGF-induced response, we re-
vealed a very strong increment of the deubiquitinase CYLD
within the tyrosine-phosphorylated complexes formed upon
EGF stimulation (32). To corroborate this finding, we per-
formed a protein immunoprecipitation using antibodies
against phosphorylated tyrosine residues followed by immu-
noblotting, thus confirming the involvement of CYLD within
the complexes engaged in response to EGF. The presence of
this DUB was very rapidly increased, being evident just 1 min
after the addition of the ligand and declining at 15 min post-
stimulation (Fig. 1A). Interestingly, this dynamic enrichment
profile parallels that of the EGFR itself, which is nevertheless
stronger. Furthermore, the signal corresponding to the en-
riched CYLD after the stimulation appeared to represent only
a small proportion of the total amount of this protein ex-
pressed in the cell (input lysate, Fig. 1A, first lane on the right),
indicating that merely a slight fraction of this deubiquitinase is
engaged in the process.
To assess whether the enrichment of CYLD is dependent
on EGFR activation, we performed the previous experiments
in the presence of Canertinib (CI1033) or Gefinitib (Iressa),
inhibitors of the EGFR kinase activity. CYLD enrichment was
abrogated when the activity of the receptor was abolished
(Fig. 1B) but not when inhibiting the two main signaling
branches downstream of the EGFR: the MAPK and the PI3K-
Akt pathways (supplemental Fig. S1A and S1B, respectively).
These results, together with the very rapid enrichment of
CYLD after the stimulation, indicated that the deubiquitinase
could play a role in the very early signaling processes after
EGFR activation, independently of the subsequent feedback
events.
CYLD Deficiency Impairs the Ubiquitination of Early Protein
Effectors of the EGF Pathway—Taking into account the ubiq-
uitin hydrolase activity of CYLD and that many of the proteins
in the EGFR signaling network undergo ubiquitination, includ-
ing K63 polyubiquitination (41–43), we reasoned that CYLD
could be responsible for deubiquitinating EGFR signaling pro-
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FIG. 1. CYLD engagement in EGFR signaling. A, CYLD enrichment in the tyrosine-phosphorylated complexes upon EGF stimulation in
HeLa cells observed by immunoprecipitation (IP) with antiphosphotyrosine (pTyr) antibodies followed by immunoblotting with indicated
antibodies. WCL-whole cell lysate. B, Same as in A, in the presence of the EGFR kinase inhibitors Iressa and CI1033. C, Efficiency of CYLD
silencing in HeLa cells. The mRNA (left) and protein (right) levels of CYLD in cells expressing scrambled shRNA (shControl) or shRNA specific
to CYLD (shCYLD) as estimated by qPCR and Western blotting, respectively. D, Effect of CYLD silencing on the overall ubiquitination profile
of the EGF-activated proteins. Lysates from wild type (WT), shControl and shCYLD HeLa cells were subjected to IP with anti-pTyr antibodies,
followed by immunoblotting (IB) with indicated antibodies. See also supplemental Fig. S1.
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teins following ligand stimulation. To examine that, we si-
lenced the expression of CYLD, achieving at least 80% de-
crease at the mRNA and protein levels (Fig. 1C) and efficiently
depleted CYLD from the EGF-dependent tyrosine-phosphor-
ylated complexes (as shown in supplemental Fig. S1C). We
next explored the impact of the silencing on the ubiquitination
status of the proteins involved in the EGF pathway. Surpris-
ingly, we found that the downregulation of the deubiquitinase
did not lead to an increase, but rather diminished the overall
ubiquitination signal of the engaged proteins after EGF addi-
tion (Fig. 1D). To gain deeper insight into this intriguing ob-
servation, we resolved to explore the EGF-induced ubiquiti-
nation events upon CYLD downregulation in a system-wide,
unbiased manner.
We used quantitative MS-based proteomics coupled to
StUbEx, a strategy that has proven successful for large-scale
investigation of ubiquitination events (33). Briefly, in the
StUbEx system the endogenous ubiquitin is replaced by a dual
tagged version containing a tandem 6xHis sequence and a Flag
tag, whereas the total pool of ubiquitin in the cell remains at
physiological levels. Ubiquitinated proteins can then be en-
riched through a two steps procedure, making use of the 6xHis
and Flag tags contained within their ubiquitin moieties (33).
We combined StUbEx with shRNA silencing of CYLD and
stable isotope labeling by amino acids in cell culture (SILAC)
(44) to provide a quantitative proteomic view of the changes in
protein ubiquitination upon the downregulation of the DUB
(Fig. 2A). We performed 4 triple SILAC experiments corre-
sponding to two biological replicas (each replica consisted of
two triple SILAC experiments; Fig. 2A) and consistently quan-
tified 1812 protein groups across them (FDR0.01; Fig. 2B
and supplemental Table S1). Only these proteins quantified in
all four SILAC experiments were used for the subsequent
analysis. Considering that the ubiquitinated proteome is of
relatively low abundance in the cell (45), the obtained extent of
quantified proteins was rather satisfactory. In addition, the
quantitation reproducibility of the measurements was very
high, with Pearson correlation values between the conditions
common to all 4 SILAC experiments (medium over light) rang-
ing between 0.92 and 0.96 (supplemental Fig. S2A and sup-
plemental Table S1). Gene ontology (GO) analysis of the iden-
tified proteins demonstrates that there is no bias of the
technique for any molecular network or pathway (supplemen-
tal Fig. S2B and supplemental Table S2), as their associated
biological processes were mostly metabolic and organizational,
representing the general functions of the cell. Moreover, the
enriched proteins originated from different sub-cellular loca-
tions, covering from cytosol to nuclear and membrane organ-
elles (supplemental Fig. S2C and supplemental Table S2),
hence displaying no bias for a particular subcellular fraction.
To identify potential regulatory effects of CYLD in the mo-
lecular characters of the EGF pathway, we focused our anal-
ysis on proteins whose ubiquitination status significantly
changed in response to the growth factor in the control cells
and compared their corresponding enrichment to the CYLD-
silenced condition. Applying very stringent criteria (signifi-
cance B, p  0.001 for each replica), we detected a set of 11
protein groups with consistently increased EGF-dependent
ubiquitination in control cells (Fig. 2C, supplemental Fig. S3A,
S3B and supplemental Table S3), in agreement with previous
studies on the EGF-dependent ubiquitinome (33, 43). Accord-
ingly, the GO-term annotations for these 11 proteins in re-
spect to function and localization were related to the EGFR/
ErbB signaling pathways and the corresponding membrane
structures and complexes (supplemental Fig. S3C, S3D and
supplemental Table S4). Interestingly, all 11 proteins dis-
played much lower levels of enrichment in response to EGF
from the CYLD-silenced cells (shCYLD) compared with the
cells with normal CYLD expression (shControl) (Fig. 2C). To
visualize more clearly the effect of CYLD downregulation on
the ubiquitination status of these molecular effectors, we nor-
malized the SILAC ratios from the different conditions to the
shControl-unstimulated cells (Fig. 2D and supplemental Fig.
S3E). The impact of CYLD deficiency on the EGF-induced
ubiquitination changes appeared to be the most significant
(significance B, p  0.001 in each replica) for EGFR, Cbl-b,
UBASH3B and SHC1 (supplemental Table S5).
In summary, the unbiased investigation of the ubiquitination
signaling through StUbEx and quantitative proteomics al-
lowed us to decipher the effect of CYLD silencing in the
ubiquitination events following EGF stimulation. Notably, the
results suggested an indirect role of CYLD in the RTK path-
way, as the downregulation of this DUB triggered an unex-
pected decrease in the EGF-dependent ubiquitination state of
several major molecular characters of the pathway including
the EGFR, Cbl-b, UBASH3B, and SHC1.
CYLD is Phosphorylated on Tyr15 upon EGF Stimulation—A
great part of the signaling cascades subsequent to the RTKs
activation rely on protein-protein interactions mediated through
the phosphorylation of tyrosine residues and proteins contain-
ing PTB or SH2 domains (46, 47). Our previous results dem-
onstrated the involvement of CYLD within the phospho-tyro-
sine protein complexes following EGF stimulation (Fig. 1A).
However, this DUB does not contain any PTB or SH2 domains
and, hence, we hypothesized that its EGF-dependent enrich-
ment was caused by its own tyrosine phosphorylation. To
examine that, we used a SILAC-based approach coupled to
immunoprecipitation of CYLD from wild type (WT) HeLa cells
that were either left unstimulated or treated with EGF for 6
min (Fig. 3A). To discriminate potential background signals,
shCYLD cells were utilized for the light (Lys0/Arg0) condition
in our experimental design. The SILAC ratios corresponding
to the CYLD protein were more than 20-fold higher in the WT
over CYLD-silenced cells, correlating well with our earlier
estimation of 80% silencing efficiency, whereas the enrich-
ment of CYLD in the WT cells 6EGF/unstimulated remained
unchanged as expected (Fig. 3B and supplemental Table S6).
Several serine-phosphorylated peptides derived from CYLD
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FIG. 2. SILAC-based quantitative proteomics analysis of ubiquitinated proteins in control and CYLD-silenced cells using the StUbEx
system. A, Experimental workflow. SILAC-labeled shControl and shCYLD HeLa cells expressing 6xHis-Flag-tagged ubiquitin instead of
endogenous ubiquitin were stimulated with EGF for 6 min, where indicated. Ubiquitinated proteins were enriched by sequential purification
using nickel-affinity chromatography and anti-Flag antibodies, digested in-solution and analyzed by LC-MS/MS. Two biological replicas were
performed for each of the indicated SILAC experiments (each biological replica corresponding to two paralleled triple SILAC experiments). B,
Overlap of the identified and quantified proteins between the two biological replicas (left) and correlation of SILAC values between the channels
common to all experiments (medium over light). See also supplemental Fig. S2. C, The group of 11 proteins with most significant ubiquitination
changes in response to growth factor stimulation and the comparison of their corresponding EGF/Unstimulated ratios in control and
CYLD-silenced cells. D, Ubiquitination status of the 11 proteins from panel C in the shControl and shCYLD cells, relative to their basal levels
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were detected in this experiment, however their phosphoryl-
ation status was unaffected by the EGF stimulation (supple-
mental Table S6). On the other hand, one of the identified
modified peptides contained a tyrosine phosphorylated site,
corresponding to the residue 15 (Fig. 3C). Manual inspection
of the mass spectrometry signal showed a large increase of its
abundance at the EGF-stimulated condition (Fig. 3D). Al-
though the intensities of the pY15-containing peptide in the
light and medium channels (corresponding to shCYLD cells
and WT unstimulated cells, respectively) were not sufficiently
above the signal-to-noise level to allow calculation of SILAC
ratios, the profile of the corresponding signals evidenced a
strong increment of at least 10-fold of the phosphorylated
form in the EGF stimulated WT cells. To estimate the fraction
of CYLD that responded to the growth factor treatment, we
calculated the stoichiometry of pY15 according to the SILAC
ratios obtained from the corresponding unmodified peptide
and the protein, as described elsewhere (48). Assuming a
pY15 6EGF/unstimulated ratio of at least 10, our results
suggested that, although at the basal state there is practically
no presence of this modified site, the EGF stimulation pro-
moted Tyr15 phosphorylation on4% or less of the total pool
of CYLD in the cells (Fig. 3E). This data, together with our
previous results (Fig. 1A), indicated again that only a small
fraction of the total cellular pool of this DUB is involved in the
EGF signaling pathway. Accordingly, CYLD appears to be ubiq-
uitously present in the cell and has been described in several
subcellular locations (49, 50), implying that it can therefore play
distinct roles dependent on its molecular environment.
Cbl-b is Recruited to the pY15 of CYLD—Taking into ac-
count that phosphorylated tyrosine residues often act as
docking sites for the interaction with SH2- or PTB domain-
containing proteins (47), we next investigated a potential abil-
ity of CYLD pY15 to recruit molecular effectors belonging to
the EGF pathway. We implemented a quantitative proteomics
approach based on an affinity pull-down strategy using as
bait the Tyr15-containing peptide in phosphorylated or un-
modified form (Fig. 4A). Two replicates were performed,
swapping the medium and heavy SILAC conditions in order to
avoid any technical bias of the method, and we quantified a
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total of 1451 protein groups in both replicas (Fig. 4B and
supplemental Table S7). CHST3, UBASH3B and Cbl-b dis-
played the most selective binding to the phosphorylated
Tyr15-containing peptide with more than 5-fold enrichment
over the non-phosphorylated version of the peptide (Signifi-
cance B, p  0.001; Fig. 4C, 4D and supplemental Table S7).
Notably, UBASH3B and Cbl-b are well known molecular char-
acters involved in the ubiquitination-dependent EGFR signal-
ing and both were already identified as proteins with a de-
creased EGF-dependent ubiquitination upon CYLD deficiency
(Fig. 2). The presence of Cbl-b was of interest, as it contains
a phospho-tyrosine binding domain and also represents a E3
ligase responsible for the ubiquitination of several effectors of
the EGF-dependent signaling cascades, including the EGFR
(51). Considering that the silencing of CYLD showed an unex-
pected impairment of the ubiquitination downstream the growth
factor stimulation and that this DUB appears to recruit Cbl-b, we
hypothesized that CYLD could be involved in the regulation of
the EGFR ubiquitination through its binding with Cbl-b. Notably,
Cbl ligases have already been described not only to interact
directly with the receptor (52, 53) but also to be recruited by
accessory adaptor proteins to the activated complexes follow-
ing EGF stimulation (54). Here, our data provided cues suggest-
ing such a role for the CYLD deubiquitinase as well.
Downregulation of CYLD Impairs EGFR Ubiquitination
Through a Deficient Recruitment of Cbl-b to the Receptor—To
corroborate the involvement of CYLD in the events described
above, we first immunoprecipitated EGFR from control and
CYLD silenced cells, followed by immunoblotting. In agree-
ment with our quantitative proteomics analysis (Fig. 2), we
observed a decrease of growth factor-dependent ubiquitina-
tion of the receptor in CYLD deficient HeLa cells (Fig. 5A). As
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further seen on Fig. 5A, the interaction of EGFR and Cbl-b
was clearly impaired in CYLD-silenced cells, consolidating the
notion that CYLD is in part responsible for the recruitment of
this E3 ligase to the receptor. Accordingly, this also resulted in
decreased levels of Cbl-b in the tyrosine-phosphorylated
complexes upon EGF stimulation (Fig. 5B). In contrast, the
engagement of the closely related E3 ligase c-Cbl, which is
also strongly involved in EGFR signaling (53), was unaffected
by the silencing of CYLD (Fig. 5B). Therefore, the impact of the
DUB on the EGF-dependent ubiquitination events appears to
be driven specifically through Cbl-b and not c-Cbl.
To further explore a potential interaction of CYLD, Cbl-b
and EGFR we used series of co-immunoprecipitation experi-
ments, which indeed demonstrate the existence of an endog-
enous complex among these proteins. The interactions of
CYLD with Cbl-b and CYLD with EGFR appeared to occur
already at basal levels in unstimulated cells and was further
strengthened by the addition of EGF (Fig. 5C, 5D), whereas
EGFR and Cbl-b did not interact in the absence of ligand (Fig.
5A). Furthermore, reduced amounts of EGFR were seen in the
Cbl-b immunoprecipitated complexes from the CYLD-si-
lenced cells (Fig. 5C), in correlation with the results from the
EGFR co-immunoprecipitation experiments shown in Fig. 5A.
Consistent with the proposed role of CYLD in assisting the
interaction between the receptor and Cbl-b, we also observed
enrichment of CYLD in the EGFR-immunoprecipitated com-
plexes upon ligand stimulation (Fig. 5D). To further confirm
these results and exclude potential cell type- specific effects,
we performed equivalent experiments in two additional cell
lines. We corroborated the interaction of CYLD with Cbl-b and
its contribution to the ubiquitination of EGFR in ovarian and
laryngeal carcinoma cells (Skov3 and Hep2, respectively),
hence demonstrating the generic nature of this unexpected
role of CYLD (Fig. 5E).
CYLD Deficiency Results in Deregulated Trafficking and
Degradation of EGFR—The ubiquitination-dependent signal-
ing events are crucial for proper endocytosis and intracel-
lular trafficking of EGFR (42) and its subsequent lysosomal
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degradation or recycling. Ubiquitin moieties are recognized
by adaptor proteins containing ubiquitin-binding domains
(UBDs) that sort the modified receptors through the endocytic
pathway (55). Consequently, an altered ubiquitination of the
EGFR can promote a de-regulated intracellular trafficking of
activated receptors. The activities of the Cbl proteins consti-
tute an essential pillar for the negative regulation of RTKs
pathways and defective binding of these E3 ligases with the
EGFR promotes a compromised ubiquitination and degrada-
tion of the receptor (56). Considering the effects of CYLD
silencing on the EGFR ubiquitination, we reasoned that this
DUB could accordingly impact the trafficking of the receptor
following ligand stimulation.
To explore this option, we transfected HeLa cells with GFP-
Rab7, a marker for late endosomes, prior to their stimulation
with EGF at different time points. As seen in Fig. 6A, the EGFR
was internalized and displayed partial co-localization with
Rab7 both in the control and in the CYLD-silenced cells.
Nevertheless, the trafficking pattern of the receptor through-
out the cells differed noticeably. Although the control cells
exhibited EGFR distribution in fewer discrete foci, the shCYLD
cells presented a more scattered image of the receptor that
spread over the cells (Fig. 6A; 30 and 60 min after EGF
addition). We also noticed much stronger EGFR signal in
CYLD-silenced cells at 2 h poststimulation, which could indi-
cate a decreased degradation of the receptor (Fig. 6B).
We next monitored EGFR cellular levels by immunoblotting
at different times after ligand stimulation, in combination with
cycloheximide treatment to prevent contribution from the de
novo protein synthesis. We observed that the amounts of the
receptor after 60 and 120 min of EGF stimulation were indeed
higher in the CYLD deficient cells (Fig. 6C). In addition, this
effect was not because of an overall increased expression of
the EGFR in the shCYLD cells. As seen by quantitative PCR
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analyses, the EGFR mRNA levels were lowered when the DUB
is silenced (Fig. 6D). Altogether, these data indicate a specific
stabilization of EGFR through a post-translational mechanism
in CYLD-silenced cells, thus in agreement with our proposed
role of CYLD in the regulation of receptor ubiquitination, im-
portant for its subsequent trafficking and degradation.
CYLD Phosphotyr15-deficient Mutant Mimics the Effects
of CYLD Silencing—To corroborate that the observed EGF-
triggered effects upon CYLD silencing are indeed driven
through the Tyr15 phosphorylation of the DUB, the following
experiments were performed. Using RNAi-resistant con-
structs, we reconstituted in the CYLD-silenced HeLa cells
either a wild type CYLD or a Y15F-CYLD mutant, in which
tyrosine 15 was exchanged with phenylalanine, hence inca-
pable of being phosphorylated at this position (Fig. 7A). The
immunoprecipitation of the reconstituted CYLD proteins un-
der stringent conditions demonstrated that the Y15F substi-
tution results in a dramatic decrease of the tyrosine-phos-
phorylation of the DUB upon EGFR stimulation (Fig. 7B),
indicating Tyr15 as the major site of CYLD phosphorylation in
response to EGF. Like the effects seen in the CYLD-silenced
cells, we observed decreased ligand dependent ubiquitination
of the EGFR in the cells reconstituted with the Y15F mutant,
together with a reduced interaction between the activated
RTK and the ubiquitin ligase Cbl-b (Fig. 7C). To simultane-
ously measure to what extent the interaction of CYLD with
Cbl-b is affected by the Y15F mutation and its consequence
for the Cbl-b association with EGFR, we implemented MS
procedure based on Parallel Reaction Monitoring (PRM) anal-
ysis coupled to immunoprecipitation of Cbl-b (supplemental
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Table S8). Compared with the CYLD WT cells, the association
of the DUB with Cbl-b was strongly impaired in the CYLD-
silenced cells as well as in the Y15F-CYLD expressing cells
(Fig. 7D). Likewise, the recruitment of EGFR to Cbl-b was also
diminished to more than 50% when the DUB was either
downregulated or Y15F mutated (Fig. 7D). We next examined
the levels of EGFR in the cells following 1 and 2 h treatment
with the ligand and observed that the receptor is slightly
stabilized in the Y15F-CYLD cells, like the CYLD-silenced
cells (Fig. 7E). To obtain quantitative estimate of this obser-
vation we utilized PRM measurements, which also indicated a
significant decrease in the degradation of EGFR when CYLD
is either silenced in the cells or incapable of being phosphor-
ylated on Tyr15 (Fig. 7F).
DISCUSSION
This study aimed to understand the engagement of the
tumor suppressor CYLD deubiquitinase within the EGF-acti-
vated complexes and its impact on the ubiquitination events
in the pathway. Here, we demonstrate that CYLD is necessary
for proper EGF-dependent ubiquitination of several well-
known effectors of the EGFR pathway, including the receptor
itself, UBASH3B and Cbl-b. We identified an EGF-dependent
phosphorylation of Tyr15 on CYLD, a modification that cre-
ated a docking site for the E3 ligase Cbl-b, thereby allowing
the assembly of additional Cbl-b to the activated EGFR. Ac-
cordingly, the silencing of CYLD or the substitution of its
Tyr15 with a phosphorylation-incapable residue promoted a
decrease in the recruitment of the ligase to the receptor,
triggering an impaired ubiquitination of EGFR, its posterior
trafficking and degradation.
Although the function of CYLD in NFkB signaling is well
explored (15, 16), its role in the RTKs signaling, particularly
downstream of the EGFR, is less understood. Earlier work
from our group initially pointed to a potential involvement of
CYLD in the EGFR pathway (32). More recently, CYLD was
revealed as a key character for integrating EGF and integrin-
dependent signals for the formation of dorsal ruffles in fibro-
blasts (57). Interestingly, the crosstalk of these molecular
networks also resulted in the tyrosine phosphorylation of
CYLD, albeit trough distinct molecular mechanisms com-
pared with our current study. EGF stimulation and fibronectin-
dependent activation of 1 integrin signaling were both re-
quired for the observed tyrosine phosphorylation of CYLD and
although the exact sites of modification were not elucidated,
it appeared not to involve Tyr15 (57).
In contrast, our study identified a specific role of CYLD,
through its Tyr15 phosphorylation, in the molecular cascade
downstream of EGFR. Of note, this site has previously been
identified in a large-scale proteomic screen; nonetheless, the
investigation of CYLD was out of the scope of the study and
thus not explored (58). Here, we demonstrated that Cbl-b is
recruited to the phosphorylated Tyr15 of CYLD and this inter-
action is necessary for the proper engagement of the ubiquitin
ligase to the receptor upon EGF stimulation. Accordingly, we
observed compromised recruitment of Cbl-b to the activated
EGFR in CYLD-silenced or CYLD Y15F-expressing cells,
which resulted in deficient ubiquitination and subsequent
degradation of the receptor. It should be noted that previous
research has shown that RNAi-based silencing of Cbl-b re-
sults in similar EGFR stabilization (59), and that the interaction
of Cbl-b with EGFR as an important factor for the degradation
of the activated receptor complexes (60).
Interestingly, the contribution of CYLD to the ubiquitination
signaling downstream of this RTK appears to be driven spe-
cifically through the Cbl-b and not c-Cbl, as the later was not
recruited to the CYLD pTyr15 and its engagement to the
activated complexes was unaffected by the silencing of the
DUB. These two closely-related proteins, despite exerting
redundant functions, seem to be subjected to different regu-
latory mechanisms (51, 61, 62) and CYLD could indeed
contribute to their differential modulation. In the context of
EGF-dependent pathway, both Cbl-b and c-Cbl have been
reported to directly interact with the activated EGFR through
its phosphorylated tyrosine residues (51, 52). However, an
additional association of the E3 ligases to the receptor could
be facilitated by the Grb2 adaptor protein as well (54). Cer-
tainly, Grb2 deficiency promotes a reduced recruitment of
c-Cbl to the EGFR with a subsequent impairment of its ubiq-
uitination and trafficking (63). Grb2-mediated association of
Cbl-b to EGFR is not explored, to our knowledge, being the
interaction between Cbl-b and Grb2 only described in the
context of TCR stimulation (64). It is possible that the recruit-
ment of additional Cbl-b to activated EGFR is controlled by
CYLD instead, similarly as Grb2 does for the related ligase
c-Cbl. Future investigations on the importance of CYLD’s
deubiquitinating activity in the process, the role of the basal
association of CYLD with Cbl-b in the absence of EGF stim-
ulation or the underlying mechanisms of differential recruit-
ment of the two closely related ubiquitin ligases could provide
further insights into the complex interplay that control the
fine-tuned regulation of EGFR trafficking and degradation.
EGFR pathway represents a central molecular network in
cellular physiology, controlling key processes such as prolif-
eration and migration. To orchestrate adequate cellular re-
sponses, the EGF-dependent signaling cascades are sub-
jected to a tight regulation that is frequently found altered in
various human cancers. Understanding the molecular events
controlling EGFR signaling constitutes the key for its manage-
ment in case of alteration. Being best described as a tumor
suppressor in the NFkB pathway, the role of CYLD in the
EGFR axis remained however elusive. In the NFkB pathway,
CYLD directly removes K63-polyubiquitin chains from key
molecular effectors, such as TRAF2, TRAF6, and NEMO (15,
16). These K63-polyubiquitin chains facilitate protein-protein
interactions that, hence, are inhibited by the action of CYLD,
resulting in decreased signal transduction and diminished
translocation of NFkB to the nucleus. We uncover herein an
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additional molecular strategy utilized by CYLD for the nega-
tive regulation of another tumorigenic signaling network,
namely the one controlled by EGFR. Here, CYLD appears to
control the fine-tuned regulation of EGFR trafficking and deg-
radation by assisting in the association of the E3 ubiquitin
ligase Cbl-b with EGFR, thereby modulating the amplitude of
ubiquitination on the receptor and several other major players
in the EGFR network.
The unbiased proteomic surveys used in our work prove to
be efficient for addressing complex regulatory mechanisms in
a systematic manner, opening the line to a new understanding
of the captivating and sometimes, like the case with CYLD,
counterintuitive nature of the fine-tuned modulation of cellular
signaling.
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